Display options
Cite
Andrade PHS, Santos ADS, Souza CAS, et al. Risk factors for adverse drug reactions in pediatric inpatients: a systematic review. Ther Adv Drug Saf. 2017;8(6):199-210doi: 10.1177/2042098617702615.
Andrade, P. H. S., Santos, A. D. S., Souza, C. A. S., Lobo, I. M. F., & da Silva, W. B. (2017). Risk factors for adverse drug reactions in pediatric inpatients: a systematic review. Therapeutic advances in drug safety, 8(6), 199-210. https://doi.org/10.1177/2042098617702615
Andrade, Paulo Henrique Santos, et al. "Risk factors for adverse drug reactions in pediatric inpatients: a systematic review." Therapeutic advances in drug safety vol. 8,6 (2017): 199-210. doi: https://doi.org/10.1177/2042098617702615
Andrade PHS, Santos ADS, Souza CAS, Lobo IMF, da Silva WB. Risk factors for adverse drug reactions in pediatric inpatients: a systematic review. Ther Adv Drug Saf. 2017 Jun;8(6):199-210. doi: 10.1177/2042098617702615. Epub 2017 Apr 25. PMID: 28607669; PMCID: PMC5455844.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Drug Saf. 2017 Jun;8(6):199-210. doi: 10.1177/2042098617702615. Epub 2017 Apr 25.

Risk factors for adverse drug reactions in pediatric inpatients: a systematic review.

Therapeutic advances in drug safety

Paulo Henrique Santos Andrade, Adriano da Silva Santos, Carlos Adriano Santos Souza, Iza Maria Fraga Lobo, Wellington Barros da Silva

Affiliations

  1. Laboratório de Ensino e Pesquisa em Farmácia Social (LEPFS), Departamento de Farmácia, Universidade Federal de Sergipe, Av. Marechal Rondon, S/n - Jardim Rosa Elze, São Cristóvão - SE, Brazil.
  2. Universidade Federal de Sergipe, Aracaju, Sergipe, Brazil.
  3. Hospital Universitário de Sergipe, Aracaju, Sergipe, Brazil.

PMID: 28607669 PMCID: PMC5455844 DOI: 10.1177/2042098617702615

Abstract

BACKGROUND: The main objective of the present systematic review is to identify potential risk factors for adverse drug reactions (ADRs) through prospective cohort studies in pediatric inpatients.

METHODS: The data search was done in the following electronic databases PubMed/MEDLINE; Scopus; LILACS and Web of Science from the earliest record until 31 May 2015. Two reviewers independently screened each study and one of them assessed the methodological quality according to the Newcastle-Ottawa scale for cohort studies. The data extraction was conducted according to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) initiative for cohort studies.

RESULTS: The only risk factor observed in all studies was the increase in the number of prescription drugs. However, other factors were identified, such as the increase in the length of stay or the number of low- or high-risk drugs prescribed, use of general anesthesia and oncological diagnosis. The cumulative incidence of ADR was 16.4% (95% confidence interval: 15.6 to 17.2). The main professional responsible for ADR identification was the pharmacist and the dominant category among the ADRs were gastrointestinal disorders. In addition, analgesics, antibacterial agents and corticosteroids were the drug classes commonly associated with ADRs. The methodology used in this study was tried to homogenize the data extracted; however, this was not sufficient to correct the discrepancies so it was not possible to perform a meta-analysis.

CONCLUSIONS: The increase in the number of prescription drugs was the main risk factor in this population. However, additional studies are required to identify the risk factors for ADRs in pediatric inpatients.

Keywords: child; cohort studies; drug-related side effects and adverse reactions; hospitals; risk factors

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

  1. J Pediatr. 2008 Feb;152(2):153-5 - PubMed
  2. Eur J Clin Pharmacol. 2012 May;68(5):801-10 - PubMed
  3. World Health Organ Tech Rep Ser. 1972;498:1-25 - PubMed
  4. Br J Clin Pharmacol. 2001 Jul;52(1):77-83 - PubMed
  5. Acta Paediatr. 1999 Sep;88(9):965-8 - PubMed
  6. Br J Clin Pharmacol. 2014 Mar;77(3):545-53 - PubMed
  7. Emerg Med J. 2003 Jan;20(1):54-60 - PubMed
  8. Syst Rev. 2015 Jan 01;4:1 - PubMed
  9. PLoS One. 2012;7(3):e24061 - PubMed
  10. J Clin Pharmacol. 2006 Aug;46(8):945-51 - PubMed
  11. Drug Saf. 2009;32(1):19-31 - PubMed
  12. BMJ Open. 2013 Feb 19;3(2):null - PubMed
  13. Pharmaceutics. 2011 Feb 07;3(1):53-72 - PubMed
  14. Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):457-64 - PubMed
  15. Lung India. 2011 Apr;28(2):152-3 - PubMed
  16. Epidemiology. 2007 Nov;18(6):805-35 - PubMed
  17. Pharmacoepidemiol Drug Saf. 2006 Sep;15(9):635-40 - PubMed
  18. Med Clin (Barc). 2010 Oct 9;135(11):507-11 - PubMed
  19. BMC Med. 2013 Nov 07;11:237 - PubMed
  20. Eur J Clin Pharmacol. 2012 Dec;68(12 ):1657-66 - PubMed
  21. Br J Clin Pharmacol. 2014 May;77(5):873-9 - PubMed

Publication Types